Disclosed is a pharmaceutical preparation for prophylactic and/or healing tranasdermal application of cholinesterase reactivators which reactivators contain a substance and/or a mixture of substances selected from the group containing 1-(2-hydroxyiminomethylpyridinium)-3-(4-carbamoylpyridinium)-2- -oxapropane pralidoxime methoxime obidoxime trimedoxime or a mixture of at least one of these cholinesterase reactivators with at least one cholinolytic substance selected from the group containing atr...

Use of 2-methyl-1-(1-piperidinyl)- 1-(2-thienyl) cyclohexane (I) in racemic diasteroisomeric or enantiomeric form in pharmaceutical compositions to limit or inhibit the effects of neurotoxic compounds or those containing neurotoxin is new. (I) is preferably used with \- 1 anticholinergic anticonvulsant or cholinesterase reactivator. Suitable anticholinergics are atropine scopolamine atropine N-oxide dihexyverine and tiemonium methyl sulphate. Suitable anticonvulsants include phenobarbital primi...